INTRODUCTION: Mutation testing for the MEN1 gene is a useful method to diagnose and predict individuals who either have or will develop multiple endocrine neoplasia type 1 (MEN 1). Clinical selection criteria to identify patients who should be tested are needed, as mutation analysis is costly and time consuming. This study is a report of an Australian national mutation testing service for the MEN1 gene from referred patients with classical MEN 1 and various MEN 1-like conditions. RESULTS: All 55 MEN1 mutation positive patients had a family history of hyperparathyroidism, had hyperparathyroidism with one other MEN1 related tumour, or had hyperparathyroidism with multiglandular hyperplasia at a young age. We found 42 separate mutations and six recurring mutations from unrelated families, and evidence for a founder effect in five families with the same mutation. DISCUSSION: Our results indicate that mutations in genes other than MEN1 may cause familial isolated hyperparathyroidism and familial isolated pituitary tumours. CONCLUSIONS: We therefore suggest that routine germline MEN1 mutation testing of all cases of "classical" MEN1, familial hyperparathyroidism, and sporadic hyperparathyroidism with one other MEN1 related condition is justified by national testing services. We do not recommend routine sequencing of the promoter region between nucleotides 1234 and 1758 (Genbank accession no. U93237) as we could not detect any sequence variations within this region in any familial or sporadic cases of MEN1 related conditions lacking a MEN1 mutation. We also suggest that testing be considered for patients <30 years old with sporadic hyperparathyroidism and multigland hyperplasia.
INTRODUCTION: Mutation testing for the MEN1 gene is a useful method to diagnose and predict individuals who either have or will develop multiple endocrine neoplasia type 1 (MEN 1). Clinical selection criteria to identify patients who should be tested are needed, as mutation analysis is costly and time consuming. This study is a report of an Australian national mutation testing service for the MEN1 gene from referred patients with classical MEN 1 and various MEN 1-like conditions. RESULTS: All 55 MEN1 mutation positive patients had a family history of hyperparathyroidism, had hyperparathyroidism with one other MEN1 related tumour, or had hyperparathyroidism with multiglandular hyperplasia at a young age. We found 42 separate mutations and six recurring mutations from unrelated families, and evidence for a founder effect in five families with the same mutation. DISCUSSION: Our results indicate that mutations in genes other than MEN1 may cause familial isolated hyperparathyroidism and familial isolated pituitary tumours. CONCLUSIONS: We therefore suggest that routine germline MEN1 mutation testing of all cases of "classical" MEN1, familial hyperparathyroidism, and sporadic hyperparathyroidism with one other MEN1 related condition is justified by national testing services. We do not recommend routine sequencing of the promoter region between nucleotides 1234 and 1758 (Genbank accession no. U93237) as we could not detect any sequence variations within this region in any familial or sporadic cases of MEN1 related conditions lacking a MEN1 mutation. We also suggest that testing be considered for patients <30 years old with sporadic hyperparathyroidism and multigland hyperplasia.
Authors: S U Goebel; C Heppner; A L Burns; S J Marx; A M Spiegel; Z Zhuang; I A Lubensky; F Gibril; R T Jensen; J Serrano Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: A P Dackiw; G J Cote; J B Fleming; P N Schultz; P Stanford; R Vassilopoulou-Sellin; D B Evans; R F Gagel; J E Lee Journal: Surgery Date: 1999-12 Impact factor: 3.982
Authors: W Karges; K Jostarndt; S Maier; A Flemming; M Weitz; A Wissmann; B Feldmann; H Dralle; P Wagner; B O Boehm Journal: J Endocrinol Date: 2000-07 Impact factor: 4.286
Authors: J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs Journal: Nat Genet Date: 2002-11-18 Impact factor: 38.330
Authors: D Bartsch; I Kopp; A Bergenfelz; H Rieder; K Münch; K Jäger; Y Deiss; A Schudy; P Barth; R Arnold; M Rothmund; B Simon Journal: Eur J Endocrinol Date: 1998-10 Impact factor: 6.664
Authors: M R Hobbs; A R Pole; G N Pidwirny; I B Rosen; R J Zarbo; H Coon; H Heath; M Leppert; C E Jackson Journal: Am J Hum Genet Date: 1999-02 Impact factor: 11.025
Authors: J Poncin; R Abs; B Velkeniers; M Bonduelle; M Abramowicz; J J Legros; A Verloes; M Meurisse; L Van Gaal; C Verellen; L Koulischer; A Beckers Journal: Hum Mutat Date: 1999 Impact factor: 4.878
Authors: Lee F Starker; Tobias Akerström; William D Long; Alberto Delgado-Verdugo; Patricia Donovan; Robert Udelsman; Richard P Lifton; Tobias Carling Journal: Horm Cancer Date: 2012-04 Impact factor: 3.869
Authors: B Han; Z Y Song; J J Wu; W Liu; B L Liu; X P Ye; X Chen; C M Pan; H Y Xu; L Li; H Zhu; Y L Lu; W L Wu; M D Chen; H D Song; J Qiao Journal: J Endocrinol Invest Date: 2012-04-05 Impact factor: 4.256
Authors: O Vierimaa; A Villablanca; A Alimov; M Georgitsi; A Raitila; P Vahteristo; C Larsson; A Ruokonen; E Eloranta; T M L Ebeling; J Ignatius; L A Aaltonen; J Leisti; P I Salmela Journal: J Endocrinol Invest Date: 2009-03-26 Impact factor: 4.256